Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Gran

Event · Earnings
Also in this documentGuidance · reaffirm

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 6, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IOVA
Bullish
high confidence
Mentioned
$IOVA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IOVABullishHigh
01

Why it matters

The most tradable elements are the record quarterly revenue and gross margin, plus management’s decision to review FY26 revenue guidance and update it in Q3. Additional FDA fast track designation and multiple trial/regulatory updates can further influence valuation expectations for lifileucel and related programs.

02

Market read

A primary quarterly financial disclosure with a guidance review and multiple regulatory/pipeline catalysts, likely driving near-term repricing of IOVA’s revenue trajectory and probability-weighted pipeline value.

03

What to watch

The filing emphasizes operational efficiencies and demand trends, but traders should watch for any one-time items affecting gross margin and the timing/likelihood of future regulatory milestones that could shift revenue phasing.

Relevance 7/10Novelty 9/10Timing: today’s SEC 8-K, pre-market/early session context for IOVA
AlphAI · Earnings readIOVA · second quarter 2026 · ended June 30, 2026

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

✓Strong quarter

Record revenue, 66% year-over-year total product revenue growth, a 56% gross margin, and continued U.S. Amtagvi demand supported a review of FY26 revenue guidance.

Revenue
$99.3M
U.S. Amtagvi revenue
~$91 million
Gross margin · other
56%
FY26 outlook
$350 million to $370 million, under review
GM Improvements in gross margin are expected to continue, excluding occasional one-time items.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenueother$99.3M––
Total product revenueother~$99 million39%66%
Gross marginother56%––
Research and Development (R&D) expensesotherdecreased by ~6%decreased by ~6%–
Cash positionother~$304 million––

Segments

SegmentRevenueq/qy/y
U.S. Amtagvi revenueContinued U.S. Amtagvi demand, supported by a new marketing campaign and an expanded sales team, drove increased adoption across a growing ATC network and referrals toward earlier treatment.~$91 million––
Global Proleukin revenueGlobal Proleukin revenue is expected to grow during the remainder of 2026.~$9 million––

FY26 outlook

  • Revenue$350 million to $370 million, under review
  • Gross marginImprovements in gross margin are expected to continue, excluding occasional one-time items.
  • NoteAn update to FY26 total revenue guidance will be provided during the third quarter.
  • NoteCurrent cash is expected to fund operations into 2H28.
  • NoteAt least 110 ATCs are expected to be active by the end of 2026.
  • NotePotential approval of the MAA in Switzerland is expected in 1H27.
  • NoteProgram updates for IOV-LUN-202 are expected in 4Q26.
  • NoteA supplemental Biologics License Application (sBLA) submission for IOV-LUN-202 is planned in 2027.
  • NoteInitial data from investigator-sponsored trials in CSCC and MCC are expected in 1H27.

What drove it

  • Total product revenue increased 66% from 2Q25 and 39% from 1Q26.
  • Gross margin reflected higher Amtagvi sales volume, continued cost optimization, and maturing internal manufacturing efficiencies.
  • R&D expenses decreased by ~6% compared to 1Q26, driven by continued operational efficiencies during the fourth straight quarter of improvements.
  • Record Amtagvi demand was catalyzed by a new marketing campaign and an expanded sales team.
  • The authorized treatment center network has grown to more than 95 U.S., Canadian, and Australian ATCs.
  • Unaided physician awareness of Amtagvi has nearly tripled during the last year.
  • Amtagvi turnaround time is 31 days or less using the centralized commercial manufacturing process approved by FDA for TIL therapy.

Concerns

  • FY26 total revenue guidance of $350 million to $370 million is under review rather than updated in this release.
  • Gross-margin improvement guidance excludes occasional one-time items.
  • The U.K. MAA was resubmitted in early July and remains under expedited MHRA review for potential approval later in 2026.
  • The European Medicines Agency MAA resubmission for Amtagvi in advanced melanoma is on track for 2027.
  • Several pipeline programs remain in enrollment, early clinical development, or registrational studies.

What to watch

  • The third-quarter update on FY26 total revenue guidance.
  • Whether gross-margin improvements continue as expected, excluding occasional one-time items.
  • Progress toward at least 110 active ATCs by the end of 2026 and growth in community ATCs.
  • Potential U.K. Amtagvi approval later in 2026 and the expected Swiss MAA decision in 1H27.
  • IOV-LUN-202 program updates expected in 4Q26 and the planned 2027 sBLA submission.
  • SARATOGA results scheduled for an oral presentation at ESMO in Madrid, Spain, from October 23–27, 2026.
  • Initial investigator-sponsored trial data in CSCC and MCC expected in 1H27.

Balance sheet and cash flow

  • As of June 30, 2026, Iovance’s cash position was ~$304 million.
  • Cash, cash equivalents, short-term investments, and restricted cash as of June 30, 2026.
  • Current cash is expected to fund operations into 2H28.

Analysis

Iovance reported record second-quarter revenue of $99.3 million. Total product revenue was reported at approximately $99 million, up 66% from approximately $60 million in 2Q25 and 39% from approximately $71 million in 1Q26. U.S. Amtagvi revenue was approximately $91 million, while Global Proleukin revenue was approximately $9 million. The release attributes the result to continued U.S. Amtagvi demand, increased awareness, a new marketing campaign, an expanded sales team, and greater adoption across the authorized treatment center network.

Margin execution improved alongside revenue growth. Gross margin was 56%, excluding depreciation and amortization, reflecting higher Amtagvi sales volume, cost optimization, and maturing internal manufacturing efficiencies. R&D expenses decreased by approximately 6% compared with 1Q26, which management described as the fourth straight quarter of improvements. The reported combination of higher revenue, improving gross margin, and lower sequential R&D expense points to continued operating-efficiency progress.

Commercial infrastructure continues to expand. The ATC network exceeded 95 U.S., Canadian, and Australian centers, with community ATCs representing a third of the network. Iovance expects at least 110 ATCs to be active by the end of 2026. Internationally, the Australian marketing authorization application was approved, the U.K. application was resubmitted in early July under expedited review, and a Swiss decision is expected in 1H27. These regulatory and network developments are central to the next phase of Amtagvi access expansion.

Management is reviewing its FY26 total revenue guidance of $350 million to $370 million based on second-quarter sales and current demand trends, but did not issue a revised range in this release. It expects gross-margin improvements to continue, excluding occasional one-time items. The company reported a cash position of approximately $304 million as of June 30, 2026, consisting of cash, cash equivalents, short-term investments, and restricted cash, and stated that current cash is expected to fund operations into 2H28.

The clinical pipeline added regulatory and development milestones. FDA Fast Track Designation was granted for lifileucel in soft tissue sarcomas, while IOV-LUN-202 enrollment is nearly complete in pivotal cohorts and program updates are expected in 4Q26. The key near-term operating issues are the third-quarter revenue-guidance update, sustained gross-margin improvement, ATC activation, international regulatory progress, and forthcoming pipeline data and program updates.

Management, verbatim

Second-quarter revenue reached a record $99.3 million with gross margin of 56%, driven by continued U.S. Amtagvi demand,

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer

Not in the filing

stated, not guessed
  • GAAP gross profit, operating income or loss, net income or loss, and diluted EPS were not provided in the supplied filing text.
  • Non-GAAP operating income or loss, net income or loss, and EPS were not provided in the supplied filing text.
  • Prior-year and prior-quarter gross margin were not provided.
  • Amtagvi prior-year revenue and prior-quarter revenue were not provided. The release states Amtagvi revenue was up 40% from 4Q25, but does not provide the corresponding revenue amount.
  • Operating cash flow and free cash flow were not provided.
  • Debt was not provided.
  • Share repurchases, dividends, and other capital-return amounts were not provided.
  • FY26 operating-expense guidance and tax-rate guidance were not provided.
  • A revised FY26 revenue-guidance range was not provided.
  • A previous outlook section was not provided; therefore, no reported-versus-prior-guidance comparison is included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

This SEC 8-K (Item 2.02) reports Iovance Biotherapeutics’ second quarter 2026 results and provides corporate, commercial, and pipeline updates.

Company-level read

Ticker impact

$IOVABullishHigh confidence
Context

IOVA reported record 2Q26 revenue of about $99.3M, 56% gross margin, and is reviewing FY26 revenue guidance to $350M-$370M.

Expected impact

Likely positive bias for IOVA as traders focus on record revenue, improving gross margin, and the implied strength in U.S. Amtagvi demand, though the guidance review adds some uncertainty.

Evidence & confidence

The filing is a primary disclosure (SEC 8-K) with specific financial datapoints (revenue, gross margin) and a concrete management action (reviewing FY26 guidance) tied to demand trends, plus FDA fast track for lifileucel.

Market effects

Reinforces investor appetite for commercial-stage cell therapy economics (margin expansion, manufacturing efficiency) and can lift sentiment for TIL therapy peers.

Limited direct regional impact, but UK/EU regulatory progress can influence European biotech sentiment around later-2026 approvals.

International regulatory milestones (Australia approval, UK expedited review, Switzerland expected in 1H27) highlight global scaling momentum for oncology cell therapies.

Counterpoint

Guidance is not raised, it is being reviewed, so the market may overreact to the record quarter while underweighting potential risks to sustaining demand or manufacturing throughput.

Key entities

  • IOVANCE BIOTHERAPEUTICS, INC.

    Commercial-stage TIL therapy company reporting 2Q26 results, margin improvement, and a FY26 guidance review.

  • lifileucel (TIL therapy)

    Program receiving FDA Fast Track Designation for soft tissue sarcomas and advancing across multiple solid tumor indications.

  • Amtagvi (commercial TIL therapy)

    U.S. commercial revenue driver with record demand and expanding authorized treatment center network.

  • FDA

    Granted Fast Track Designation for lifileucel in soft tissue sarcomas.

Every IOVA earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$SLSHighAI 8/10

SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too

BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.

$IOVAHighAI 8/10

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance Biotherapeutics (IOVA) reported Q3 2026 earnings with a loss of 5 cents per share, narrower than estimates. Revenue rose 80.1% YoY to $121.5M, driven by Amtagvi sales. R&D costs fell 34.4% YoY. IOVA reaffirmed 2026 revenue guidance of $410M-$420M. Shares fell 11% despite strong results.

$IOVAMedAI 8/10

Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122

Iovance Biotherapeutics (IOVA) reported Q3 2026 revenue of $122M, up 80% YoY, with Amtagvi US revenue crossing $100M. Interim CEO Vogt confirmed no impact from past maintenance issues and expects sequential growth. CFO Roche noted improved profitability. Proleukin sales rose to $20M, aligning with Amtagvi demand. LUN-202 data expected next year, with BLA submission planned for 2027. Community hospital infusions are growing, currently at 1/3 of total. Cash runway extended into 2029.

$IOVAMed

Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial Data

Iovance Biotherapeutics (IOVA) announced that its treatment lifileucel showed strong efficacy in advanced soft tissue sarcomas, according to a pilot study. The FDA granted lifileucel fast track designation for these sarcomas. IOVA reported Q3 2026 revenue of $121.47M and a net loss of $22.27M. The company is expanding its TIL platform beyond melanoma into other solid tumor indications.

$IOVAHighAI 8/10

IOVANCE BIOTHERAPEUTICS, INC. (IOVA): Corporate Overview November 2026 Exhibit 99.1

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Other Events. Corporate Overview November 2026 Exhibit 99.1 Exhibit 99.1 Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meani

$IOVAHighAI 8/10

Iovance (IOVA) Q3 2026 Earnings Call Transcript

Iovance (IOVA) reported Q3 2026 revenue of $122M, up 80% YoY, with AMTAGVI sales at $102M. The company expects to expand its ATC network to 110+ centers by year-end. Clinical trials for lifileucel in non-small cell lung cancer and sarcoma showed promising results, with FDA fast-track designations granted. Iovance plans sBLA submissions in 2027 and 2028-2029. The company's cash runway is expected to extend into 2029.